Trials / Active Not Recruiting
Active Not RecruitingNCT06062420
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 316 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dostarlimab | Dostarlimab will be administered. |
| DRUG | Belrestotug | Belrestotug will be administered. |
| DRUG | Nelistotug | Nelistotug will be administered. |
| DRUG | Remzistotug | Remzistotug will be administered. |
Timeline
- Start date
- 2023-11-14
- Primary completion
- 2026-09-01
- Completion
- 2027-12-31
- First posted
- 2023-10-02
- Last updated
- 2026-04-09
Locations
108 sites across 20 countries: United States, Argentina, Brazil, Canada, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Norway, Poland, Portugal, Romania, South Korea, Spain, Taiwan, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06062420. Inclusion in this directory is not an endorsement.